Dr Fendrick asked panelists what they think about the idea of centers of excellence for specific cancers and an evidence-based steerage.
Dr Fendrick asked panelists what they think about the idea of centers of excellence for specific cancers and an evidence-based steerage. “There may be a value in having a centralized guidance of treatments adapted to a particular patient,” said Dr Ribas. Dr Ribas also discussed the effect future agents being developed for the treatment of melanoma will have on the market. He says prices will be adapted to the benefit due to more competition in the marketplace.
“Perhaps there is some relief on the horizon in terms of pricing because of competition,” said Dr Weber. “Classic essence of capitalism.”
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care
June 23rd 2025This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Read More